RenovoRx, Inc. — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022; filed March 31, 2023. This is an annual report, not a standalone fourth-quarter report. RenovoRx is a clinical-stage biopharmaceutical company developing RenovoGem, a combination of intra-arterial gemcitabine and its RenovoCath delivery system, for solid tumors. The company had no approved products or product-sales revenue.
Key financial results and liquidity
| Metric | FY2022 / year-end | FY2021 / comparison |
|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue |
| Research and development expense | $4.301 million | $3.039 million |
| General and administrative expense | $5.649 million | $2.632 million |
| Total operating expenses / operating loss | $9.950 million | $5.671 million |
| Net loss | $9.889 million; $1.09 per share | $6.324 million; $1.21 per share |
| Net cash used in operating activities | $8.811 million | $5.916 million |
| Cash and cash equivalents | $4.391 million | $15.192 million |
| Short-term marketable securities | $2.049 million | None |
| Total assets / liabilities / stockholders’ equity | $7.265 million / $1.102 million / $6.163 million | $16.287 million / $0.938 million / $15.349 million |
Revenue-based margins are not meaningful because the company reported no product-sales revenue. Year-end cash, cash equivalents and short-term securities totaled $6.440 million. The company had no convertible notes outstanding at year-end; its 2020 and 2021 notes converted in connection with the August 2021 IPO. Management said year-end funds were not expected to cover operating, investing and financing needs for at least the next 12 months, and the auditor highlighted substantial doubt about the company’s ability to continue as a going concern.
Material changes and developments
- Net loss increased by $3.565 million, or 56%, from 2021. Operating expenses rose 75%; R&D increased 42% and G&A increased 115%. Higher G&A reflected post-IPO professional services, insurance, staffing and legal costs. R&D growth included increased preclinical spending; clinical development expense was broadly unchanged, with slower enrollment offsetting higher consulting costs.
- Operating cash use increased from $5.916 million to $8.811 million. Cash and cash equivalents declined by $10.801 million during 2022; investing cash use of $2.032 million principally reflected purchases of U.S. Treasury bills.
- After year-end, on March 30, 2023, the company agreed to a registered direct offering and concurrent private placement expected to generate approximately $5 million in gross proceeds, before fees and expenses. The transaction included common shares or pre-funded warrants and warrants to purchase additional shares.
- As of March 24, 2023, 9,100,448 common shares were outstanding. At December 31, 2022, 2,786,995 warrants were outstanding with a $10.80 exercise price.
Clinical outlook, risks and unusual items
- TIGeR-PaC Phase III trial: The first planned interim analysis, announced in March 2023, reported median overall survival from randomization of 16 months for RenovoGem versus 10 months for IV gemcitabine plus nab-paclitaxel, based on 23 and 22 patients, respectively. The analysis reported a positive trend at 24 weeks, but did not reach the stated threshold to stop the trial early (p=0.051). The DMC recommended continuing without modification and reported no safety concerns. The results are interim and subject to further analysis and verification.
- The study protocol was changed to use SBRT, following higher induction-phase dropout among IMRT patients. The company’s modified analysis plan targets 114 randomized SBRT patients and 86 deaths, rather than the original 200-patient design. The company said it had not discussed the protocol amendment or modified analysis plan with the FDA and could not assure FDA agreement. As of March 20, 2023, 48 SBRT patients had been randomized; management anticipated enrollment in 2024 and final readout in 2025. A second interim analysis was estimated for mid-2024, but timing depends on deaths occurring.
- The company planned a Phase II/III trial of RenovoGem for extrahepatic cholangiocarcinoma, incorporating durvalumab, subject to finalizing the protocol and regulatory developments. RenovoGem has FDA orphan drug designations for pancreatic cancer and cholangiocarcinoma; designation does not constitute approval.
- Management expects continuing operating losses and higher research, development and administrative expenses. The company has no committed financing source or credit facility. Further capital may require equity or debt issuance, collaboration arrangements, or delay or reduction of development programs. The March 2023 offering provides additional gross proceeds but does not remove the disclosed financing and going-concern risks.
- Other key risks include clinical and regulatory uncertainty, reliance on third parties and a single-source RenovoCath manufacturer, ability to recruit patients and scale manufacturing, reimbursement and market adoption uncertainty, competition, and patent protection. The company reported no material pending legal proceedings.
- Management identified material weaknesses in internal control over financial reporting, including inadequate accounting staffing and expertise, insufficient written policies and procedures, management-review gaps and lack of segregation of duties. Disclosure controls were concluded to be ineffective; management said remediation was underway and expected to continue during 2023. The independent auditor gave an unqualified opinion on the financial statements but did not opine on internal control effectiveness.
Most important facts for investors to verify
- Review the complete audited financial statements and going-concern disclosures, including the company’s actual cash runway and use of proceeds from the March 2023 financing.
- Track TIGeR-PaC enrollment, event counts, final statistical analysis, safety data and FDA feedback on the amended protocol and modified analysis plan.
- Confirm whether the eCCA protocol is finalized, whether the trial launches, and how durvalumab affects its design, costs and timing.
- Assess potential dilution from the March 2023 offering, outstanding warrants and future financing needs.
- Monitor remediation of internal-control material weaknesses and any subsequent changes in disclosure-control effectiveness.